A Phase 1 interventional study of LAS41008 120 mg / Fumaderm® 120 mg in Psoriasis, sponsored by Almirall, S.A.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-22.
Sponsored by Almirall, S.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Psoriasis by Almirall, S.A. — 2 open to participants now, 3 under way, none of them phase 3. Psoriasis · Almirall, S.A..
Among the 20 studies in Psoriasis by Almirall, S.A., this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2016, is the only one in phase 1, and was the 10th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 20 studies in Psoriasis by Almirall, S.A. are open now, in 1 country. Recruiting first, the newest first:
Almirall, S.A. · Sites in Austria
Ages 18–99
Almirall, S.A. · Sites in Austria
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 3 · Phase 4 3
First in 2010; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 36 across the 14 interventional studies, 201 across the 6 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Psoriasis by Almirall, S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine how the organism affects MMF (metabolite of dimethyl fumarate [DMF]) after single oral dose administration of LAS41008 120 mg gastroresistant tablet and Fumaderm® 120 mg gastro-resistant tablet under fasting and fed conditions. The study also aims to assess the safety of the study treatments.
The present study will be conducted to further investigate the pharmacokinetics (PK) of LAS41008 (containing DMF) after single oral dose administrations of a 120 mg gastro-resistant tablet under fed and fasting conditions.
Two previous Phase 1 studies allowed exploring the PK of LAS41008 30 mg and 120 mg separately after multiple dosing. In the current study, an improved bioanalytical method will allow the detection of lower MMF concentrations, and thus the same gastro-resistant tablet formulation (LAS41008) as used in the previous Phase 1 study will be investigated, but on a larger population and after single oral dose administration. Only the higher LAS41008 dose (120 mg) will be tested, as this is the formulation to be most frequently used during a standard treatment course for psoriasis with LAS41008. Similarly, single oral doses of Fumaderm® 120 mg (defined mixture of DMF and calcium (Ca), magnesium (Mg), and zinc (Zn) salts of ethylhydrogenfumarate (EHF, mono-ethyl fumarate (MEF)) will be tested in order to provide better comparative PK data. The comparison of LAS41008 and Fumaderm® PK will be evaluated in an exploratory manner.
The study will be conducted according to a randomised, open-label, four-way complete crossover, single dose design in 32 healthy male and female subjects. Up to 4 discontinued subjects may be replaced in case of early dropouts or a dropout rate greater than 15% (5 or more subjects). Gender balance will also be taken into consideration to ensure that roughly the same number of males and females are randomised. Upon inclusion into the treatment phase, each subject will be randomly allocated to one of four treatment sequences in a 4x4 Williams design. On Day 1 of each treatment period subjects will receive a single oral dose of either LAS41008 120 mg gastro-resistant tablet or Fumaderm® 120 mg gastro-resistant tablet under fasting or fed conditions. The drug administrations will be separated by a wash-out-phase of 7 ± 3 days. Blood sampling for PK will be performed until 24 hours after each study drug administration.
The Informed Consent Form (ICF) will be signed before any study activity, including the withdrawal of any concomitant medication (at least 2 weeks before this screening visit) if required for study participation. The Screening Visit will take place within 28 days before randomisation and after signing of the ICF to check subjects' eligibility. In each period, subjects will be admitted to the study centre from the morning of Day -1 until discharge in the morning of Day 2 (after collection of last blood sampling for PK).
The duration of study participation for each subject from Visit 1 (Screening) to the Follow-up Visit 7 ± 3 days after the last study drug administration is estimated to be approximately 7 to 10 weeks considering study visits time-window allowance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)
Drug: LAS41008 120 mg / Fumaderm® 120 mg
LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)
Drug: LAS41008 120 mg / Fumaderm® 120 mg
Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)
Drug: LAS41008 120 mg / Fumaderm® 120 mg
LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)
Drug: LAS41008 120 mg / Fumaderm® 120 mg
Drug page: Dimethyl Fumarate
Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
Also known as: LAS41008: DMF / Fumaderm®: DMF + Ca, Mg and Zn salts of EHF
Area under the concentration-time curve from zero to time t (AUC(0-t)) of LAS41008 120 mg/Fumaderm® 120 mg
t is the time of the last concentration measured
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
Cmax of LAS41008 120 mg/Fumaderm® 120 mg
Maximum plasma concentration
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
tmax of LAS41008 120 mg/Fumaderm® 120 mg
Time to reach maximum plasma concentration
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
tlag of LAS41008 120 mg/Fumaderm® 120 mg
Lag time
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
Area under the concentration-time curve from zero to infinity (AUC) of LAS41008 120 mg/Fumaderm® 120 mg
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
Extrapolated part of AUC (%AUCext) of LAS41008 120 mg/Fumaderm® 120 mg
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
t1/2 of LAS41008 120 mg/Fumaderm® 120 mg
Elimination half-life
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
Formation clearance of a drug to a metabolite (CL/f) of LAS41008 120 mg/Fumaderm® 120 mg
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
Vz/f of LAS41008 120 mg/Fumaderm® 120 mg
Apparent volume of distribution during terminal phase after non-intravenous administration
Time frame: Within 1 hour pre-dose and post-dose at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 16 and 24 hours (29 blood samples in each period)
Blood pressure
Time frame: at Visit 1 (screening), 1 hour pre-dose and approximately at the same time on Day 2 of each period
Pulse rate
Time frame: at Visit 1 (screening), 1 hour pre-dose and approximately at the same time on Day 2 of each period
Oral body temperature
Time frame: at Visit 1 (screening) and pre-dose on Day 1 of each period
12-lead electrocardiogram (ECG) parameters
Time frame: on Day 2 of each period
Physical examination findings
Time frame: abbreviated on each admission and Day 2 of Period 4, and complete at Visit 1 (screening) and at the Follow-up Visit (7 ± 3 days after the study drug administration of the last treatment period)
Safety laboratory tests values (standard haematology, blood chemistry [clinical chemistry], urinalysis [sediment], and pregnancy test)
Note: Serum pregnancy test at Visit 1 (screening) and Follow-Up Visit; urine pregnancy test pre-dose
Time frame: at Visit 1 (screening) and on Day 2 of each period, and at the Follow-Up Visit (7 ± 3 days after the study drug administration of the last treatment period)
Overall tolerability (number of participants with adverse events (AEs) at the Follow-up Visit)
Time frame: Follow-up Visit (7 ± 3 days after the study drug administration of the last treatment period)
Number of participants with adverse events/serious adverse events (SAEs)
Time frame: from signature of the informed consent until the Follow-up Visit (7 ± 3 days after the study drug administration of the last treatment period)
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2016, a primary completion of Oct 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate